In the first seven months of this year, the pharmaceutical company led the A-shares with nearly 20 times the gain.

In the first seven months of this year, Vantai Bio and Stats were the top two stocks to rise, according to Wind.
among them, Wanta Bio led the A-shares with a nearly 20-fold gain.
Also based on thinking financial data compiled from January 1 to July 31 this year, the rise and fall of the top 50 list, Wantay Bio rose as high as 1985.00 percent, also belongs to the pharmaceutical sector of The British Medical, Kanghua Bio, Tibet Pharmaceuticals, Susse Bio, Zhende Medical and other pharmaceutical stocks are also in the top 10, up more than 400 percent.
is enough to reflect the pharmaceutical sector's capital-favorites.
, which led the rise in A-shares, went public on April 29, 2020.
data show that Wanta bio-main in-body diagnostic reagents, in-body diagnostic instruments and vaccine research and marketing.
, in the field of in-body diagnosis, the company's products are mainly HIV diagnostic reagents, hepatitis B diagnostic reagents, etc. , in the field of vaccines, the company's products mainly include cervical cancer vaccines.
March this year, Wante Bio, in collaboration with Xiamen University, developed a new coronavirus anti-medical kit based on the Caris200 fully automatic light-emitting platform, which is immediately used for diagnosis through national emergency approval.
In addition, the company's first domestic HPV vaccine has also been on the market, "testing reagents and vaccines" dual concept, so that Wantay bio received high attention from the market;
Data show that since the listing, Wanta Bio has harvested 25 consecutive gains and stops, the in-cap share price reached 296.8 yuan, as of the close of August 7, Wanta Bio reported 265.3 yuan / share, up 4.04% against the trend, the total market value has reached 115 billion yuan.
addition to Wante Bio, Kanghua Bio, a vaccine concept unit that also belongs to the pharmaceutical sub-sector, also performed well, rising as much as 753.65 percent in the first seven months of this year.
company's main products are rabies vaccine and meningitis vaccine, of which rabies vaccine accounted for up to 97% of the main.
July 16, the ceiling sold for 3.18 billion yuan, the next day for 4.26 billion yuan.
share price has since risen, to 996 yuan, becoming the second-highest-priced stock after Maotai.
are the second-largest stocks in the vaccine concept stock, and while their gains have soared, the boss behind them has surged by nearly 100 billion yuan.
of which the majority shareholder of Wantay Bio is Health Hall Co., Ltd., the actual controller of the .
Zhong directly owns 78.8 million shares of Wante Bio, plus through the indirect shareholding of Health Hall, a total of 74.23 percent of Wante Bio's shares.
Wante Bio's listed offering price was 8.75 yuan, and Zhong 's pre-issue shareholding market value was 2,816 million yuan, rising to 296.8 yuan on August 4, a cumulative increase of 32.92 times over the issue price, and Zhong 's shareholding market value was 95.528 billion yuan.
, the controlling shareholder of Kanghua Bio, owns 24.93 per cent of the company.
's issue price was 70.37 yuan, with a total share capital of 60 million shares, and Wang Zhentao's pre-issue market value was 1,052 million yuan.
's August 4 high rushed to 996 yuan, compared with the issue price of a cumulative increase of up to 13.15 times, the company's total market value reached 59.7 billion yuan.
it is worth mentioning that Wang Zhentao's Okang International was listed on the Shanghai Stock Exchange as early as 2012 and currently has a market capitalisation of 3.4 billion yuan.
In the eyes of some industry people, vaccine concept stocks are more suspected of speculation, and face the risk of research and development progress is not up to expectations, or overseas related companies to take the lead in research and development success, it is recommended that investors do not touch vaccine stocks at present.
there are also investors who believe that vaccine demand will be released in the future, optimistic about the opportunity of vaccine concept stocks.
.